Latest News
You are: Home > News & Events > Latest News > Optibiotix Expands into Australasia
Fri 21st July
Optibiotix Expands into Australasia
A YORK company that creates compounds for the food industry to tackle dietary related health problems has agreed its first overseas supply deal outside of Europe.

Optibiotix Health, based a York Science Park, has agreed to develop and supply three different products containing its LPLDL product, to Pharmabiota NZ.

The firm’s LPLDL strain has been developed as a bacteria to be used by the food industry as probiotics for general health benefits in the gut.

Pharmabiota, based in New Zealand, provides scientifically validated innovative products through its growing retail pharmacy partner network throughout New Zealand and Australia.

The agreement, which includes a minimum initial purchase of 30,000 boxes, covers the initial development and supply of three products, packaged and released by Pharmabiota, containing LPLDL in different dosage forms.

It is expected the deal with provide initial moderate levels of income for Optibiotix, growing to six figure revenues in the second year.

The agreement is the first step outside Europe in a business to business strategy of bringing OptiBiotix’s science together with a partner’s national brand portfolio and market presence to serve multiple consumer healthcare and pharmaceutical markets around the world.

Stephen O’Hara, chief executive of OptiBiotix, said: “We are at the start of the commercialisation process but are really excited at the high level of interest in our products.”

For the full story, please visit the York Press website.

Space for your business
Why York Science Park?
Your conference or meeting
Events at York Science Park